Immune and experimental infection responses of dairy cows vaccinated with the combination of six Staphylococcus aureus proteins that are expressed during bovine intramammary infection and a triple adjuvant

“…123 Ster et al developed a vaccine with recombinant proteins constituting Emulsigen-D, a CpG oligodeoxynucleotide, and indolicidin which, when tested, exhibited a sustained reduction in MSCC, although there was no difference in the S. aureus count. 124 Recently, Cote-Gravel et al developed a genetically stable SCV to disable its ability to adapt and revert to the invasive phenotype and inactivated vraG gene, essential for S. aureus virulence during IMIs. This study highlighted the potential application of this double mutant as a live-attenuated component in vaccines to cell-mediated immune responses against S. aureus-mediated IMIs.…”

Section: Macrolidesmentioning

confidence: 99%

“…Ster et al developed a vaccine with recombinant proteins constituting Emulsigen-D, a CpG oligodeoxynucleotide, and indolicidin which, when tested, exhibited a sustained reduction in MSCC, although there was no difference in the S . aureus count . Recently, Côté-Gravel et al developed a genetically stable SCV to disable its ability to adapt and revert to the invasive phenotype and inactivated vraG gene, essential for S .…”

Section: Current Strategies For Controlling Mastitismentioning

confidence: 99%

Bovine Mastitis: Examining Factors Contributing to Treatment Failure and Prospects of Nano-enabled Antibacterial Combination Therapy

Majumder

Eckersall

George

2023

ACS Agric. Sci. Technol.

View full text Add to dashboard Cite

Bovine mastitis, primarily caused by microbial infections of cow mammary glands leading to inflammation, is the costliest disease in the dairy industry. The severity and the responsiveness of mastitis to treatment depend on the dynamic interplay between the host, pathogen, and environmental factors. Evidently, the prospects of managing mastitis with conventional antibiotic treatment and disease management strategies are grim with the emergence of antimicrobial resistance (AMR) and the prevalence of virulence characteristics such as biofilm formation and intracellular survival among the persistent pathogens. Thus, there is a need for safe and economically viable alternate therapies capable of targeting broad-spectrum pathogens displaying AMR and virulence characteristics. Recent progress in the application of nanotechnology in drug delivery and infection control provides unprecedented opportunities for resolving recalcitrant infections. While the advantages of nanotechnology have been exploited for therapeutic delivery in humans, the potential of nanotechnology is yet to be realized in animal agriculture, especially for treating bovine mastitis. This review provides an overview of risk factors and pathogenesis associated with bovine mastitis that challenge the success of current treatment strategies and highlights how those unique challenges could be exploited for designing effective nano-enabled antibacterial combination therapy for bovine mastitis treatment.

show abstract

Immune and experimental infection responses of dairy cows vaccinated with the combination of six Staphylococcus aureus proteins that are expressed during bovine intramammary infection and a triple adjuvant

Cited by 2 publications

References 33 publications

An overview on mastitis-associated Escherichia coli: Pathogenicity, host immunity and the use of alternative therapies

An overview on mastitis-associated Escherichia coli: Pathogenicity, host immunity and the use of alternative therapies

Bovine Mastitis: Examining Factors Contributing to Treatment Failure and Prospects of Nano-enabled Antibacterial Combination Therapy

Contact Info

Product

Resources

About